Market Cap 2.58B
Revenue (ttm) 517.15M
Net Income (ttm) 66.35M
EPS (ttm) N/A
PE Ratio 25.81
Forward PE 27.37
Profit Margin 12.83%
Debt to Equity Ratio 0.00
Volume 672,300
Avg Vol 855,652
Day's Range N/A - N/A
Shares Out 79.46M
Stochastic %K 5%
Beta 1.91
Analysts Strong Sell
Price Target $47.50

Company Profile

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was f...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 650 243 6300
Fax: 650 243 6388
Address:
6000 Shoreline Court, Suite 300, South San Francisco, United States
BillionerOfKing
BillionerOfKing Mar. 4 at 1:44 AM
$VCYT Current Stock Price: $35.07 Contracts to trade: $35.0 VCYT Mar 20 2026 Call Entry: $0.45 Exit: $0.69 ROI: 52% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ZacksResearch
ZacksResearch Feb. 26 at 4:53 PM
$VCYT just delivered a clean beat — and the market noticed 🚀 Q4 earnings jumped 47% year over year, revenues climbed 18.5%, margins improved, and the company beat estimates across the board. Shares are already rising after hours — that’s what strong execution looks like. See what’s driving the momentum and whether it can continue 👉 https://www.zacks.com/stock/news/2876043/veracyte-q4-earnings-beat-estimates-revenues-grow-yy-stock-rises?cid=sm-stocktwits-2-2876043-teaser-35320&ADID=SYND_STOCKTWITS_TWEET_2_2876043_TEASER_35320
0 · Reply
ZacksResearch
ZacksResearch Feb. 26 at 3:53 PM
$VCYT gains after Q4 earnings beat — what's fueling the momentum? 🚀 Veracyte's Q4 EPS of 53 cents soared past estimates by 30.06%, with revenues climbing 18.5% YoY, driven by Decipher and Afirma growth of 27% and 16%, respectively. Discover the full earnings breakdown here 👉 https://www.zacks.com/stock/news/2876043/veracyte-q4-earnings-beat-estimates-revenues-grow-yy-stock-rises?cid=sm-stocktwits-2-2876043-body-35321&ADID=SYND_STOCKTWITS_TWEET_2_2876043_BODY_35321
0 · Reply
erevnon
erevnon Feb. 26 at 12:17 PM
Needham maintains Veracyte $VCYT at Buy and raises the price target from $44 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
PhishTourFunds
PhishTourFunds Feb. 26 at 2:31 AM
$VCYT Up over 50% from here
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 25 at 9:16 PM
$VCYT Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.52 up 642.86% YoY • Reported revenue of $140.64M up 18.55% YoY • Veracyte is reiterating 2026 total revenue guidance of $570M to $582M, representing 10% to 13% growth, with adjusted EBITDA margin expected to be approximately 25%.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Feb. 22 at 11:04 PM
$DNA at $9 seeing low volume, while $VCYT trading at $36 with slightly above-average volume. VCYT showing 300% more strength compared to DNA. Are investors favoring established players over smaller ones in the Genomics space?
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 20 at 3:56 PM
$VCYT RSI: 39.79, MACD: -1.4563 Vol: 1.90, MA20: 37.34, MA50: 40.68 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BioTechHealthX
BioTechHealthX Feb. 8 at 5:05 PM
$VCYT Veracyte (NASDAQ:VCYT) is emerging as a top genomic diagnostics stock as demand for precision cancer testing rises in 2026. Here’s what’s driving the story, why the platform looks scalable, and what investors are watching next. https://biotechhealthx.com/biotech-news/is-it-still-safe-to-invest-in-veracyte-vcyt/
0 · Reply
PersephonePivots
PersephonePivots Feb. 4 at 9:32 AM
$VCYT molecular diagnostics, reimbursement landscape
0 · Reply
Latest News on VCYT
Veracyte, Inc. (VCYT) Q4 2025 Earnings Call Transcript

Feb 25, 2026, 10:17 PM EST - 14 days ago

Veracyte, Inc. (VCYT) Q4 2025 Earnings Call Transcript


Veracyte to Participate in Upcoming Investor Conferences

Feb 19, 2026, 5:00 PM EST - 21 days ago

Veracyte to Participate in Upcoming Investor Conferences


Veracyte: Profitable, De-Risked, And Ready To Run

Jan 16, 2026, 9:44 AM EST - 7 weeks ago

Veracyte: Profitable, De-Risked, And Ready To Run


Veracyte, Inc. (VCYT) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 11:46 PM EST - 4 months ago

Veracyte, Inc. (VCYT) Q3 2025 Earnings Call Transcript


Veracyte Announces Third Quarter 2025 Financial Results

Nov 4, 2025, 4:05 PM EST - 4 months ago

Veracyte Announces Third Quarter 2025 Financial Results


Veracyte: Q2 Earnings Brings My Position Out Of Mothballs

Aug 26, 2025, 10:18 AM EDT - 7 months ago

Veracyte: Q2 Earnings Brings My Position Out Of Mothballs


Veracyte, Inc. (VCYT) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 2:20 AM EDT - 7 months ago

Veracyte, Inc. (VCYT) Q2 2025 Earnings Call Transcript


Veracyte Announces Second Quarter 2025 Financial Results

Aug 6, 2025, 4:05 PM EDT - 7 months ago

Veracyte Announces Second Quarter 2025 Financial Results


Veracyte, Inc. (VCYT) Q1 2025 Earnings Call Transcript

May 8, 2025, 12:49 AM EDT - 11 months ago

Veracyte, Inc. (VCYT) Q1 2025 Earnings Call Transcript


Veracyte Announces First Quarter 2025 Financial Results

May 7, 2025, 4:05 PM EDT - 11 months ago

Veracyte Announces First Quarter 2025 Financial Results


Solid Growth, Soft Outlook: Why I'm Holding On Veracyte

Feb 25, 2025, 10:32 AM EST - 1 year ago

Solid Growth, Soft Outlook: Why I'm Holding On Veracyte


Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 10:53 PM EST - 1 year ago

Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript


Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 10:49 PM EST - 1 year ago

Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript


Veracyte Announces Third Quarter 2024 Financial Results

Nov 6, 2024, 4:05 PM EST - 1 year ago

Veracyte Announces Third Quarter 2024 Financial Results


BillionerOfKing
BillionerOfKing Mar. 4 at 1:44 AM
$VCYT Current Stock Price: $35.07 Contracts to trade: $35.0 VCYT Mar 20 2026 Call Entry: $0.45 Exit: $0.69 ROI: 52% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ZacksResearch
ZacksResearch Feb. 26 at 4:53 PM
$VCYT just delivered a clean beat — and the market noticed 🚀 Q4 earnings jumped 47% year over year, revenues climbed 18.5%, margins improved, and the company beat estimates across the board. Shares are already rising after hours — that’s what strong execution looks like. See what’s driving the momentum and whether it can continue 👉 https://www.zacks.com/stock/news/2876043/veracyte-q4-earnings-beat-estimates-revenues-grow-yy-stock-rises?cid=sm-stocktwits-2-2876043-teaser-35320&ADID=SYND_STOCKTWITS_TWEET_2_2876043_TEASER_35320
0 · Reply
ZacksResearch
ZacksResearch Feb. 26 at 3:53 PM
$VCYT gains after Q4 earnings beat — what's fueling the momentum? 🚀 Veracyte's Q4 EPS of 53 cents soared past estimates by 30.06%, with revenues climbing 18.5% YoY, driven by Decipher and Afirma growth of 27% and 16%, respectively. Discover the full earnings breakdown here 👉 https://www.zacks.com/stock/news/2876043/veracyte-q4-earnings-beat-estimates-revenues-grow-yy-stock-rises?cid=sm-stocktwits-2-2876043-body-35321&ADID=SYND_STOCKTWITS_TWEET_2_2876043_BODY_35321
0 · Reply
erevnon
erevnon Feb. 26 at 12:17 PM
Needham maintains Veracyte $VCYT at Buy and raises the price target from $44 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
PhishTourFunds
PhishTourFunds Feb. 26 at 2:31 AM
$VCYT Up over 50% from here
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 25 at 9:16 PM
$VCYT Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.52 up 642.86% YoY • Reported revenue of $140.64M up 18.55% YoY • Veracyte is reiterating 2026 total revenue guidance of $570M to $582M, representing 10% to 13% growth, with adjusted EBITDA margin expected to be approximately 25%.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Feb. 22 at 11:04 PM
$DNA at $9 seeing low volume, while $VCYT trading at $36 with slightly above-average volume. VCYT showing 300% more strength compared to DNA. Are investors favoring established players over smaller ones in the Genomics space?
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 20 at 3:56 PM
$VCYT RSI: 39.79, MACD: -1.4563 Vol: 1.90, MA20: 37.34, MA50: 40.68 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BioTechHealthX
BioTechHealthX Feb. 8 at 5:05 PM
$VCYT Veracyte (NASDAQ:VCYT) is emerging as a top genomic diagnostics stock as demand for precision cancer testing rises in 2026. Here’s what’s driving the story, why the platform looks scalable, and what investors are watching next. https://biotechhealthx.com/biotech-news/is-it-still-safe-to-invest-in-veracyte-vcyt/
0 · Reply
PersephonePivots
PersephonePivots Feb. 4 at 9:32 AM
$VCYT molecular diagnostics, reimbursement landscape
0 · Reply
BBraggHillBoys
BBraggHillBoys Feb. 3 at 9:19 PM
$VCYT awful
0 · Reply
PhishTourFunds
PhishTourFunds Jan. 22 at 3:57 PM
$VCYT 💪
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 20 at 12:51 PM
$VCYT RSI: 46.39, MACD: -0.1985 Vol: 1.08, MA20: 42.87, MA50: 43.30 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
PhishTourFunds
PhishTourFunds Dec. 30 at 3:38 AM
$VCYT Pullback from $50 mostly complete (weekly chart has several “air gaps”) and accumulation well underway
0 · Reply
EfficiencyExpert
EfficiencyExpert Dec. 26 at 10:12 AM
$VCYT Macro trends are relevant, yet internal execution remains the decisive catalyst. Sequential performance needs to stabilize convincingly. Momentum stabilizes only when delivery becomes predictable. The outlook strengthens only as evidence accumulates.
0 · Reply
ZacksResearch
ZacksResearch Dec. 23 at 7:37 PM
$VCYT's Afirma is outperforming, but is macro pressure a threat? 🤔 📈 Afirma's 13% volume growth and Decipher's 14th consecutive quarter of >25% YoY growth highlight strong diagnostics demand. ⚠️ Macro challenges led to an 11.6% rise in total cost of revenues, impacting growth. Discover the full story on VCYT here 👉 https://www.zacks.com/stock/news/2808193/is-this-the-right-time-to-add-veracyte-stock-to-your-portfolio?cid=sm-stocktwits-2-2808193-body-26098&ADID=SYND_STOCKTWITS_TWEET_2_2808193_BODY_26098
0 · Reply
ZacksResearch
ZacksResearch Dec. 23 at 6:37 PM
Is $VCYT finally a buy — or a value trap in disguise? ⚖️ Afirma and Decipher are driving strong test volume growth and the company sports a debt-free balance sheet, but rising macro costs and expenses are clearly tempering the outlook. Get the full risk/reward breakdown before making a move 👉 https://www.zacks.com/stock/news/2808193/is-this-the-right-time-to-add-veracyte-stock-to-your-portfolio?cid=sm-stocktwits-2-2808193-teaser-26097&ADID=SYND_STOCKTWITS_TWEET_2_2808193_TEASER_26097
0 · Reply
PhishTourFunds
PhishTourFunds Dec. 22 at 12:55 PM
$VCYT 🔥
0 · Reply
Estimize
Estimize Dec. 18 at 12:09 PM
Wall St is expecting 0.39 EPS for $VCYT Q4 [Reporting 03/02 AMC] http://www.estimize.com/intro/vcyt?chart=historical&metric_name=eps&utm_co
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 10 at 8:11 PM
$VCYT Current Stock Price: $43.12 Contracts to trade: $45 VCYT Dec 19 2025 Call Entry: $0.40 Exit: $0.76 ROI: 89% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Estimize
Estimize Dec. 2 at 9:00 PM
Wall St is expecting 0.39 EPS for $VCYT Q4 [Reporting 03/02 AMC] http://www.estimize.com/intro/vcyt?chart=historical&metric_name=eps&utm_co
0 · Reply
JarvisFlow
JarvisFlow Dec. 2 at 6:02 PM
Morgan Stanley has updated their rating for Veracyte ( $VCYT ) to Underweight with a price target of 48.
0 · Reply